Odelo (Rivaroxaban)

Rivaroxaban, the active ingredient in Odelo, is a direct factor Xa inhibitor presented as an oral tablet for oral use. It is used to reduce the risk of thromboembolic events in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism.

GNH USA supplies Odelo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rivaroxaban is indicated for several thromboembolic conditions within the anticoagulation pathway.

Atrial fibrillation (non‑valvular): reduces risk of stroke and systemic embolism. Deep vein thrombosis (DVT) treatment: facilitates clot resolution and prevents recurrence. Pulmonary embolism (PE) treatment: aids in clot dissolution and secondary prevention. Post‑operative DVT prophylaxis after hip or knee replacement: lowers incidence of postoperative clot formation.

Rivaroxaban may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Bruising or minor bleeding at sites of injury. - Nosebleeds (epistaxis). - Headache. - Gastrointestinal discomfort or dyspepsia. - Dizziness. - Anemia.

Serious or Rare Side Effects: - Severe or uncontrolled bleeding (including intracranial hemorrhage). - Spinal or epidural hematoma. - Hepatic injury or elevated liver enzymes. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Thrombocytopenia. - Hematuria (blood in urine).

Use of rivaroxaban requires careful assessment and monitoring.

Renal function assessment: adjust dosing in patients with impaired clearance. Bleeding risk evaluation: avoid in active major bleeding. Concomitant antiplatelet therapy: use caution due to additive bleeding risk. Pregnancy and lactation: avoid unless benefits outweigh potential risks. Hepatic impairment: monitor liver function and consider dose adjustments. Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Rivaroxaban interacts with several medications that can alter its anticoagulant effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine). - Other anticoagulants (e.g., warfarin, heparin). - Antiplatelet agents (e.g., clopidogrel, aspirin at high dose). - Non‑steroidal anti‑inflammatory drugs (NSAIDs) at high dose.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil). - Moderate CYP3A4 inducers (e.g., phenytoin, phenobarbital). - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs). - Azole antifungals (e.g., fluconazole). - Certain antibiotics (e.g., macrolides).